Exploring Clinical Profile & Approval Journey of EMRELIS Against Nonsquamous Non-Small Cell Lung Cancer With High c-Met Protein Overexpression

  • Introducing rationale for targeting c-Met and breaking down Teliso-V design and development, including tandem companion diagnostic development against c-Met
  • Diving into Phase II LUMINOSITY safety and efficacy readouts on clinical outcomes in NSCLC patients that lead to FDA accelerated approval
  • Highlighting lessons learned from development journey in an indication without an approved ADC therapy, and understanding what this means for other ADC programmes